Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine

The More You Know…

A 10-year study of AAV gene therapy in haemophilic dogs found genomic changes that may increase the risk of liver cancer. 

Though none of the nine dogs administered with the AAV8 or AAV9 vectors (expressing canine factor VIII) in the study showed evidence of tumors or altered liver function, the team found 1,741 unique AAV integration events in genomic DNA and expanded cell clones in five dogs, with 44 percent of integration near genes involved in cell growth. 

The authors pointed out that, though integration into the host genome has been observed in mice, non-human primates, and humans, previous studies for hemophilia B with about 10 years’ follow-up haven't reported increases in transgene expression or vector-mediated serious adverse events.

They added that their data "emphasize the importance of long-term monitoring after AAV gene therapy."

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

  1. GN Nguyen et al., “A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells”, Nat Biotech (2020). PMID: 33199875.

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine